Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 06/18/2025
Short Title (70 char) QuVa Pharma, Inc. Sugar Land, TX. Untitled Letter issued 06/18/2025
FEI Number 3012053582
Firm Name QuVa Pharma, Inc
Record Type 483
State TX
Establishment Type Outsourcing Facil
Similar Posts
FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma
On October 23, 2025, the Food and Drug Administration approved belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma whoInfusion Pump Software Recall: Baxter Removes Sigma Spectrum Infusion System Platforms
This communication is part of the Communications Pilot to Enhance the Medical Device Recall ProgramApotex Inc. – 05/09/2025
Apotex Inc. – 05/09/2025. Country: Canada. Record Type: 483GDUFA Type II API DMF Payment Receipts Report
GDUFA Type II API DMF Payment Receipts ReportFDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight LossRecommendations for Complying With Over-the-Counter Monograph Procedure for Minor Changes C001: Minor Changes to Solid Oral Dosage Forms for Certain Over-the-Counter Monograph Drugs
This guidance provides recommendations for how requestors can comply with the requirements described in the Proposed Administrative Order titled Over-the-Counter Monograph Procedure for Minor Changes C001: Minor Changes to Solid Oral Dosage Forms for Certain Over-the-Counter Monograph Drugs.